The growth in revenue from operations was driven by a strong 26.0% Y-o-Y (+22.6% Q-o-Q) growth in the US market to INR 30,929 Mn (estimated: INR 31,846 Mn); It was driven by new launches such as Mirabegron, Zituvimet and volume expansion in the base portfolio as gRevlimid also improved Q-o-Q.